AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04314661 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Arthroscopy with Mesenchymal Stem Cells + Secretome + Secretome
Description: After Arthroscopy intervention, patient recieve 10 million Allogeneic Umbilical Cord Mesenchymal Stem Cells in 2 cc NaCl, two weeks afterward, patient receive 2 cc Secretome, and four weeks later, patient receive another 2 cc Secretome. All intervention will be done via Intra-articular.
Study NCT04314661 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Arthroscopy with Secretome + Mesenchymal Stem Cells + Secretome
Description: After Arthroscopy intervention, patient recieve 2 cc Secretome, two weeks afterward patient receive 10 million Allogeneic Umbilical Cord Mesenchymal Stem Cells in 2 cc NaCl, and four weeks later, patient receive another 2 cc Secretome. All intervention will be done via Intra-articular.
Study NCT04314661 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Non Arthroscopy with Mesenchymal Stem Cells + Secretome + Secretome
Description: Without Arthroscopy intervention, patient recieve 10 million Allogeneic Umbilical Cord Mesenchymal Stem Cells in 2 cc NaCl, two weeks afterward, patient receive 2 cc Secretome, and four weeks later, patient receive another 2 cc Secretome. All intervention will be done via Intra-articular.
Study NCT04314661 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Non Arthroscopy with Secretome + Mesenchymal Stem Cells + Secretome
Description: Without Arthroscopy intervention, patient recieve 2 cc Secretome, two weeks afterward patient receive 10 million Allogeneic Umbilical Cord Mesenchymal Stem Cells in 2 cc NaCl, and four weeks later, patient receive another 2 cc Secretome. All intervention will be done via Intra-articular.
Study NCT02376933 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vertebroplasty
Description: Under imaging guidance, a fractured vertebral body is stabilized with injected bone cement.
Study NCT02376933 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy of metastatic lesions to the spine.
Study NCT02663258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Study NCT03860077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Very Low Nicotine Content Cigarettes
Description: Very Low Nicotine Content Cigarettes
Study NCT03860077 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Nicotine Content Cigarettes
Description: Normal Nicotine Content Cigarettes
Study NCT01786343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: 20 mg/m2 by vein daily for either 5 or 10 days.
Study NCT04248075 — intervention group
Intervention type: DEVICE
Intervention: Electroencephalogram
Description: Electroencephalogram is performed before, during, and 1 day after surgery in elderly patients undergoing spinal anesthesia.
Study NCT03530020 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: monolithic zirconia crowns
Description: full anatomical monolithic crowns
Study NCT03530020 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lithium silicate crowns
Description: lithium silicate glass ceramics are highly resistance to chipping
Study NCT03186807 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasonographic scan of fetal brain
Description: 1. Routine measurement of BPD, HC, OFD, cisterna magna, cerebellum, lateral ventricle(1).~   specific measurements as follow:~2. Parietoccipital fissures will be measured from the most external border of cortex to the luminar line.~3. Lateral fissure depths will be measured from the most external border of the insular cortex to the interface confirmed between the subarachnoid space and the skull.~4. Cingulate fissures will be measured in the mid-coronal plane tracing a perpendicular line from the median longitudinal fissure to the apex of the cingulate fissures.~6. Calcarine fissures will be measured in the coronal transcerebellar plane as tracing a perpendicular line from the median longitudinal fissure to the apex of the calcarine fissures.
Study NCT00112112 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FluMist
Description: The total volume of 0.5 mL was administered intranasally with a spray applicator (approximately 0.25 mL into each nostril). Each dose contained approximately 10 to 7th TCID 50 (median tissue culture infectious dose) of each of three influenza virus strains. During the 2005 enrollment period, the three 2004/2005 influenza virus strains were used: A/New Caledonia/20/99(H1N1), A/Wyoming/03/2003(H3N2), and B/Jilin/20/2003). During the 2006 and 2007 enrollment periods, the three 2005/2006 influenza virus strains were used: A/New Caledonia/20/99(H1N1), A/California/7/2004(H3N2), and B/Jiangsu/10/2003 (B/Shanghai/361/2002-like.~brief description of the arm. This element may not be necessary if the associated intervention descriptions contain sufficient information to describe the arm.
Study NCT01173536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Oral repeating dose
Study NCT00112112 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intranasal mist was composed of allantoic fluid stabilized with buffer containing sucrose, potassium phosphate, and monosodium glutamate. The total volume of 0.5 mL was administered intranasally with a spray applicator (approximately 0.25 mL into each nostril).
Study NCT04606888 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation
Description: According to the traditional Chinese medicine 15,three acupuncture points were selected as the target points: bilateral Neiguan ,Yintang and bilateral Zusanli.. A transcutaneous electrical stimulator was used to provide an altered frequency 2/100 Hz,disperse-dense waves,and adjusted intensity which was less than 10mA.
Study NCT00670540 — intervention group
Intervention type: OTHER
Intervention: procedure of Deep Vein Thrombosis (DVT) and PE (Pulmonary Embolism) diagnosis
Description: patients with a clinical suspicion of Venous ThromboEmbolism (VTE = Deep Vein Thrombosis or Pulmonary Embolism) were eligible
Study NCT04453787 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arch support orthoses with forefoot medial wedge
Description: The degree of forefoot wedge will be 3 degree. If needed, it could be adjusted. The subjects need to wear the orthoses for at least 30 hour per week during the experiment.
Study NCT04453787 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arch support orthoses
Description: The arch support of the orthoses could be adjusted depends on the evaluation of subject. The subjects need to wear the orthoses for at least 30 hour per week during the experiment.
Study NCT04453787 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Flat insole
Description: The flat insole used as a placebo intervention. The shape of this insole is flat, and made by soft EVA. It only provide shock absorbtion without any support. The subjects need to wear the orthoses for at least 30 hour per week during the experiment.
Study NCT00681811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGT-1111
Description: Patients currently dosed with 100 U/kg or 200 U/kg will continue this treatment. Patients dosed with 50 U/kg will be equally randomized to treatment on 100 U/kg or 200 U/kg. The dose will be adjusted every 6-week to account for changes in body weight.The infusion length will be dependent on the dose. Infusion of 100 U/kg will be diluted in 50 ml isotonic sodium chloride and infused over 30 minutes. Infusion of 200 U/kg will be administered in the same manner except for an infusion time of 60 minutes.
Study NCT00124605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pamidronate disodium
Description: Given IV
Study NCT00893945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DC/AAT
Description: Autologous dendritic cells that have been co-cultured with autologous apoptotic tumor (AAT) specimens.
Study NCT00893945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DC/AAT-Flu
Description: Intradermal injection of Autologous dendritic cell vaccine (DC/AAT-Flu) after co-culture with flu-infected AAT
Study NCT00893945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DC/KLH
Description: Intradermal injection of Autologous dendritic cell vaccine (DC/KLH) which have been co-cultured with Keyhole pimpit hemocyanin (KLH) as a positive control.
Study NCT03419624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: daily Insulin injections
Study NCT03419624 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: daily Insulin injections
Study NCT03419624 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin
Description: daily Insulin injections
Study NCT03419624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin, if taken before
Description: If the Patient has taken Metformin prior to enrollment, he or she will continue to take it.
Study NCT03419624 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin, if taken before
Description: If the Patient has taken Metformin prior to enrollment, he or she will continue to take it.
Study NCT03419624 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin, if taken before
Description: If the Patient has taken Metformin prior to enrollment, he or she will continue to take it.
Study NCT01627106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vernakalant
Description: Initial intravenous (IV) dose of 3 mg/kg (up to a maximum of 339 mg) over 10 minutes, followed by a 15 minute observation period and, if conversion to sinus rhythm does not occur within 15 minutes of the initial infusion, a second 10 minute infusion of vernakalant at a dose of 2 mg/kg (up to a maximum of 226 mg) will be administered.
Study NCT01627106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiodarone
Description: Administered IV as per product label
Study NCT00780390 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Autonomic Function Assessment
Study NCT00780390 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autonomic Function Assessment
Study NCT00717444 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: contingency management
Description: contingency management for abstinence plus 12-step facilitation therapy~prizes awarded for target behaviors
Study NCT00717444 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: contingency management
Description: contingency management for abstinence plus 12-step facilitation therapy and contingency management for completing healthy activities~prizes awarded for target behaviors
Study NCT02386800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ruxolitinib
Description: ruxolitinib tablets or pediatric oral solution - participants continue ruxolitinib as they received in parent study
Study NCT02386800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panobinostat
Description: panobinostat capsules - participants to continue receiving panobinostat in combination with ruxolitinib as per the parent study
Study NCT01135940 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2-octylcyanoacrylate (Dermabond) closure
Description: Standard procedure for closure of adipose/ subcutaneous layers. The subcuticular layer will be closed with a continuous 2-0 vicryl suture which will then be followed by Dermabond closure.
Study NCT04544631 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality game as adjunctive pain management tool
Description: A smart phone virtual reality-based pain alleviation tool (VR-PAT).
Study NCT00124605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arsenic trioxide
Description: Given IV
Study NCT00124605 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT04629521 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CyPass Micro-Stent
Description: The CyPass Micro-Stent is a small tube with a through-lumen designed to redirect aqueous fluid from the front into the back of the eye. The device is implanted after completion of cataract surgery.
Study NCT04629521 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract Surgery
Description: Cataract surgery involves the removal of the natural lens, which has become clouded (called a cataract), and insertion of an artificial lens (called an intraocular lens). This procedure is done through a small surgical incision in the eye.
Study NCT03662373 — intervention group
Intervention type: RADIATION
Intervention: carbon ions radiation therapy
Description: Carbon ion radiation therapy to treat adenoid cystic carcinoma, skull base (clivus) chordoma.
Study NCT00124605 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT01698671 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: InterGard Synergy Vascular Graft
Study NCT01135940 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard staple closure
Description: Standard procedure for closure of adipose/ subcutaneous layers followed by staple closure
Study NCT04386122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FABALOFEN 60
Description: Dosage: Single dose of one tablet of test product in each period. Administration: 30 minutes before administration, subjects will receive a test meal (high-fat and high-calorie) and finish this meal in 30 minutes or less. Take 1 tablet of test product with 240 mL of water. Lying position or strenuous activities are not allowed within 2 hours post dose
Study NCT04386122 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JAPROLOX TABLET
Description: Dosage: Single dose of one tablet of reference product in each period. Administration: 30 minutes before administration, subjects will receive a test meal (high-fat and high-calorie) and finish this meal in 30 minutes or less. Take 1 tablet of reference product with 240 mL of water. Lying position or strenuous activities are not allowed within 2 hours post dose
Study NCT01050764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regulatory T-cells
Description: To ameliorate the impaired immune recovery and address the significant relapse incidence in the haploidentical setting. Cells will be selected by a tandem selection process and infused on day +14. These are the enriched but naturally-occurring regulatory T cells. Possible dose cohorts and levels are:~Cohort 1~* T-reg: 1 x 10e5/kg~* T-con: 3 x10e5/kg~Cohort 2~* T-reg: 3 x 10e5/kg~* T-con: 1 x 10e6/kg~Cohort 3~* T-reg: 1 x 10e6/kg~* T-con: 3 x 10e6/kg~Cohort 4~* T-reg: 3 x 10e6/kg~* T-con: 1 x 10e7/kg
Study NCT03662373 — intervention group
Intervention type: RADIATION
Intervention: protons radiation therapy
Description: Proton radiation therapy used to treat meningioma and squamocellular rhinopharynx carcinoma
Study NCT01050764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional T-cells
Description: These are conventional (unselected) donor T-cells. Cell dosage of the infusion will be based on the CD3+ cell content and infused on day +16.
Study NCT01050764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Anti-cancer chemotherapy drug administered IV at 140 mg/m² on Day -8 prior to HSCT (a component of the conditioning regiment prior to infusion of cells)
Study NCT01050764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Anti-cancer chemotherapy drug administered IV at 10 mg/kg on Day -7 prior to HSCT (a component of the conditioning regiment prior to infusion of cells)
Study NCT01050764 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Anti-cancer chemotherapy drug administered IV at 160mg/m² on Days -6; -5; -4; and -3 prior to HSCT (a component of the conditioning regiment prior to infusion of cells
Study NCT01050764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-thymocyte globulin, rabbit
Description: Rabbit-derived antibodies against human T-cells used as transplant rejection prophylaxis. Administered at 6 mg/kg IV on Days -6; -5; -4; and -3 prior to HSCT
Study NCT01050764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CliniMACS CD34 Reagent System
Description: An in vitro medical device system that uses antibodies conjugated to magnetic beads to select and enrich for CD34+ blood stem cells from the allogeneic donor apheresis product prior to HSCT, while removing other cells that can cause GvHD. CD34+ cell dosage will be based on the participant's body weight.
Study NCT02416180 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SERETIDE MDI
Description: Commercially available SERETIDE MDI (EVOHALER) containing fluticasone propionate/salmeterol. Subjects will use MDI as 2 inhalations twice daily at the dose equivalent to their usual maintenance treatment of SERETIDE via DISKUS Inhaler.
Study NCT02416180 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo DISKUS Inhaler
Description: Placebo dry powder inhaler to be used to demonstrate the use of DISKUS inhaler at Visit 1
Study NCT02416180 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo MDI
Description: Clear liquid propellant inhaler to be used to demonstrate the use of MDI at Visit 2
Study NCT02643927 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: standard 8-weeks MBSR
Description: A 8 weekly sessions of 120 min based on the standard protocol of Kabat Zinn was performed. The adapted program did not include a one-day retreat in silence, but one session in silence plus extra kindly awareness (compassion-based) and value-based exercises. Home practice was not systematically assessed, but recommended to be of 45min per day, most of the days. It was administered by a trained (3-y experience) and certified MBSR teacher (MMPD).
Study NCT03314337 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pancreatic stent: PSOF COOK®
Description: After removing the distal pancreas, PSOF COOK will be place in the main pancreatic duct
Study NCT01449929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dolutegravir 50 mg OAD
Description: 1 x 50 mg tablet OAD
Study NCT01449929 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: darunavir 800mg OAD
Description: 2 x 400mg tablets OAD
Study NCT01449929 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ritonavir 100mg OAD
Description: 1 x 100mg tablet OAD
Study NCT01194505 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sciatic, femoral, obturator nerve blocks
Description: Ultrasound guided blocks with ropivacaine
Study NCT01194505 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sciatic nerve block, posterior lumbar plexus block
Description: Ultrasound and neurostimulator nerve blocks with ropivacaine
Study NCT04265118 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sidewards Tilting Bed
Description: Sidewards tilting of the bed is hypothesized to induce a body position change in sleeping subjects.
Study NCT04130971 — intervention group
Intervention type: OTHER
Intervention: No intervention, just observation
Description: No intervention, just observation of the differences between groups and within patients.
Study NCT03434899 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise and online support
Description: Person-centered design of a health care plan including individually adjusted physical exercise. Online support for management of health care plan.
Study NCT06614816 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oka strain varicella attenuated live vaccine
Description: lyophilized powder, subcutaneous injection
Study NCT06614816 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Oka strain varicella attenuated live vaccine
Description: lyophilized powder, subcutaneous injection
Study NCT04209127 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microwave treatment via needle antenna
Description: Microwave treatment via needle antenna, (Emprint Covidien microwave ablation system) either percutaneous or vaginally administrated
Study NCT04209127 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Embolization of uterine artery or branches thereof (routine treatment where polyvinyl alcohol particles are released into the predefined bloodstream)
Description: Embolization via percutaneous catheter
Study NCT03434899 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical exercise
Description: Person-centered design of health care plan individually adjusted physical exercise.
Study NCT03445442 — intervention group
Intervention type: PROCEDURE
Intervention: SCP
Description: Sacrocolpopexy (SCP) aims to secure the anterior vaginal wall, the uterus more or less the posterior vaginal wall using polypropylene prostheses and to secure them to the presacral ligament to restore the patient's anatomical features and improve pelvic symptoms
Study NCT03445442 — intervention group
Intervention type: PROCEDURE
Intervention: NTR
Description: Native tissue repair surgery (NTR) consist of site-specific surgical repair of the existing defect (anterior and/or posterior) using non-absorbable sutures. Specifically, anterior and/or posterior colporrhaphy for cystocele and rectocele respectively after adequate hydrodissection of the vesicovaginal or rectovaginal space.
Study NCT03445442 — intervention group
Intervention type: PROCEDURE
Intervention: VMR
Description: Vaginal mesh repair surgery (VMR) is performed using a single-incision mesh system. A single vertical incision is made in the anterior and/or posterior vaginal wall. A full-thickness dissection is performed laterally and apically to the ischial spine.